Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, suggested an observational trial weighted to emulate a clinical trial.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Patients on dialysis who take denosumab face a 36% higher risk for major cardiovascular adverse events than patients who take oral bisphosphonates, according to a study published Jan. 6 in Annals ...

a proposed denosumab biosimilar to Amgen’s PROLIA and XGEVA. GlyCoNex is a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies. The licensee ...

While patients taking the injectable denosumab (Prolia; Amgen) had 45% fewer fractures than those on bisphosphonates, their 3-year risk weighted risk ratio (RR) for MACE was 1.36 (95% CI 0.99-1.87), ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event ...